Recurrent Childhood Soft Tissue Sarcoma Recruiting Phase 1 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01552434Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTreatment